Creatine kinase MB, troponin I, and troponin T release patterns after coronary artery bypass grafting with or without cardiopulmonary bypass and after aortic and mitral valve surgery.
After the protocol was approved by the local ethics committee and informed consent was obtained, patients scheduled for CABG with (group A: 25 males; age, 66 [+ or -] 9.8 years; 11 females; age, 68 [+ or -] 11.2 years) or without (group B: 19 males; age, 61 [+ or -] 14.4 years; 4 females; age, 63 [+ or -] 5.7 years) CPB, aortic valve replacement (group C: 8 males; age, 67 [+ or -] 9.2 years; 6 females; age, 65 [+ or -] 15 years), or mitral valve replacement (group D: 6 males; age, 64 [+ or -] 13.9 years; 3 females; age, 72 [+ or -] 7.6 years) were recruited. All patients had normal renal, hepatic, and cerebral function. Exclusion criteria were recent AMI, unstable angina, and emergency procedures. Anesthesiological (10) and surgical procedures (11,12) were performed according to a fixed protocol as described earlier. A standardized CPB technique was used in groups A, C, and D (10). Postoperatively, the diagnosis AMI was accepted based on WHO criteria: electrocardiographic changes (new Q-wave >0.4 s, new ST elevation in two or more leads >0.1 mV), and a typical rise and fall of CKMB.
Blood samples were obtained before anesthesia (baseline), at the start of surgery, after release of aortic cross-clamping (CPB) or completion of grafting (off-pump), on admission to the intensive care unit, at fixed times (0200, 0700, 1400, 2100), and on day 2. After centrifugation at 10008, serum was separated and stored at -20 [degrees]C until further analysis. Total CK and CKMB were measured immediately. Total CK and CKMB activity were measured with a Vitros analyzer (Ortho). The cutoff values (COVs) were 70 U/L (men) and 50 U/L (women) for total CK, and 10 U/L for CKMB activity. Troponin I was measured using an Access (7) analyzer (COV, 0.1 [micro]g/L; Beckman) and an AxSYM (8) analyzer (COV, 2.0 [micro]g/L; Abbott Diagnostics Division). CKMB mass (COV, 5.0 [micro]g/L) and troponin T (COV, 0.1 [micro]g/L) were measured on an Elecsys 2010 (9) analyzer (Roche).
Patients were excluded from analysis if they had repeat operations, AMI, or episodes of arrhythmia. Release patterns of the examined markers were smoothed and expressed as the 2.5th, 50th, and 97.5th percentiles of the concentrations according to National Academy of Clinical Biochemistry recommendations (13). The area under the curve (AUC) for each patient was calculated using the trapezium method (14), normalized by dividing the test result by the upper limit of the reference interval (2), and compared using the Mann--Whitney U-test and the Kruskal--Wallis test. Relationships between cross-clamp time and the ADCs were tested using the Spearman rank correlation test. Analysis of covariance (ANCOVA) was used to detect differences between both CPB treatment procedures (CABG and valve replacement), using the cross-clamp time as covariate. If the necessary requirements of ANCOVA (e.g., parallelism) were not fulfilled, the difference between cross-clamp times shorter than or longer than 1 h was examined with the Mann--Whitney U-test. Statistical significance was accepted at P <0.05.
Six patients in group A and two in group B were excluded. Most markers reached the highest values at 6-8 h after baseline (Fig. 1). The values for patient groups A, B, C, and D were 23, 3.5, 44, and 50 [micro]g/L, respectively, for troponin I (AxSYM); 0.8, 0.15, 2.2, and 2.2 [micro]g/L, respectively, for troponin I (Access); 0.6, 0.15, 1.0, and 1.8 [micro]g/L, respectively, for troponin T; and 34, 8, 80 and 80 [micro]g/L, respectively, for CKMB mass. All measured values, except total CK, were significantly lower in the off-pump group (Table 1). In addition, CKMB activity, CKMB mass, and troponin were significantly lower in the CABG subgroup with one or two anastomoses than in the subgroup with three or more anastomoses (Table 1). All markers except total CK were lower in the CABG groups than in the valve-replacement groups. Comparison between the aortic and mitral valve groups showed no differences in the examined markers. However, taking into account the small numbers, a trend toward difference seemed present, which was probably related to the more extensive surgical intervention in the mitral group.
The mean ([+ or -] SD) cross-clamp times were lower in the CABG group (55 [+ or -] 21 min) than in the valve replacement group (81 [+ or -] 27 min). The Spearman rank correlation test demonstrated significant relationships (P <0.001) with the cross-clamp time for all biochemical markers. The markers CKMB mass, troponin I (AxSYM), and troponin I (Access) did not show homogeneity of slopes (parallelism). Comparison between the CABG and valve replacement groups with cross-clamp times shorter than as well as longer than 1 h showed statistical differences only for times longer than 1 h (P <0.002). In contrast, when we used ANCOVA, troponin T was different for cross-clamp times both shorter than and longer than 1 h.
[FIGURE 1 OMITTED]
This study demonstrates that the release patterns of cardiac markers in patients after cardiac surgery depends on the type of surgery. Cardiac troponins I and T were not significantly increased from baseline in the off-pump CABG group. In contrast, all procedures using CPB produced significantly higher values of the examined cardiac markers. Release of troponins in CABG patients was lower than in valve surgery patients. Thus, the lowest values were obtained for the off-pump group, the highest values for patients undergoing valve surgery. The values for the CABG + CPB group were in between.
All patients undergoing heart surgery may experience a certain amount of myocardial injury. This injury is multifactorial. Its causes include use of CPB, surgical technique, manipulation of the heart, aortic cross-clamping, and preexisting coronary artery disease. The amount of cardiac damage is indicated in the AUC of the release pattern of a cardiac marker (15). This study shows that all types of surgery except off-pump CABG produce increases beyond the upper limit of the reference interval of each cardiac marker and thus produce measurable cardiac damage as a result of the procedure itself. These data show that total CK does not discriminate between the various groups. In contrast to both troponin I methodologies, troponin T discriminates between the CABG patients with one or two, and the CABG patients with three or more distal grafts.
The observed differences in marker release patterns for surgery (e.g., CABG and valve replacement) with cross-clamp times shorter and longer than 1 h suggest that myocardial damage after cross-clamp times >1 h is not related just to cross-clamping: other factors, such as insufficient cardioplegic protection and severity of left ventricle hypertrophy, may also be involved. Troponin T release was different for all cross-clamp times in CABG compared with valve replacement patients. This result and the finding that troponin T can discriminate between CABG patients with one or two and three or more distal grafts suggest that troponin T may be more sensitive as a marker for myocardial damage after cardiac surgery.
Most previous studies reported results from heterogeneous groups of patients undergoing bypass and/or valve replacement surgery did not discriminate between patients with and without complications, or investigated only one new cardiac marker (16-20). Moreover, differences between generations of technology and the need for better calibration and standardization of troponin I make comparison of these studies difficult.
In conclusion, we report that the release patterns of cardiac markers after uncomplicated heart surgery depend on the type of surgery and the circumstances during surgery. Off-pump CABG did not produce a significant increase in any of the tested markers. In contrast, patients undergoing CABG with CPB showed significant increases in the tested markers, whereas valve replacement surgery produced the highest concentrations of cardiac markers. Because of a lack of analytical standardization and calibration of the various cardiac marker methodologies, we recommend that each institution should determine its own release patterns of cardiac markers for cardiac surgical procedures.
(1.) Multicenter Study of Perioperative Ischemia (MCSPI) Research Group. Effects of acadesine on the incidence of myocardial infarction and adverse cardiac outcomes after coronary artery bypass graft surgery. Anesthesiology 1995;83:658-73.
(2.) Swaanenburg JCJM, Klaase JM, De Jongste MJL, Zimmerman KW, Ten Duis HJ. Troponin I, troponin T, CKMB-activity and CKMB-mass as markers for the detection of myocardial contusion in patients who experienced blunt trauma. Clin Chim Acta 1998;272:171-81.
(3.) Bodor GS, Porter S, Landt Y, Ladenson JH. Development of monoclonal antibodies for an assay of cardiac troponin I and preliminary results in suspected cases of myocardial infarction. Clin Chem 1992;38:2203-14.
(4.) Katus HA, Looser S, Hallermayer K, Remppis A, Scheffold T, Borgya A, et al. Development and in vitro characterization of a new immunoassay of cardiac troponin T. Clin Chem 1992;38:386-93.
(5.) Yau TM, Weisel RD, Mickle DA, Komeda M, Ivanov J, Carson S, et al. Alternative techniques of cardioplegia. Circulation 1992;86(Suppl 2):377-84.
(6.) Mariani MA, Boonstra PW, Grandjean JG, Gu YJ. Minimally invasive coronary surgery at the beginning of the new millennium. Cardiologica 1998;43: 883-8.
(7.) Christenson RH, Apple FS, Morgan DL, Alonsozana GL, Mascotti K, Olson M, et al. Cardiac troponin I measurement with the ACCESS immunoassay system: analytical and clinical performance characteristics. Clin Chem 1998;44:52-60.
(8.) Apple FS, Maturen AJ, Mullins RE, Painter PC, Pessin-Minsley MS, Webster RA, et al. Multicenter clinical and analytical evaluation of the AxSYM troponin-I immunoassay to assist in the diagnosis of myocardial infarction. Clin Chem 1999;45:206-12.
(9.) Muller-Bardorff M, Hallermayer K, Schroder A, Ebert C, Borgya A, Gerhardt W, et al. Improved troponin T ELISA specific for cardiac troponin T isoform: assay development and analytical and clinical validation. Clin Chem 1997; 43:458-66.
(10.) Van der Maaten JMAA, Epema AH, Huet RCG, Hennis PJ. The effect of midazolam at two plasma concentrations on hemodynamics and sufentanil requirement in coronary artery surgery. J Cardiothorac Vasc Anesth 1996; 10:356-63.
(11.) Mariani MA, Boonstra PW, Grandjean JG, van der Schans C, Dusseljee S, van Weert E. Minimally invasive coronary artery bypass grafting without cardiopulmonary bypass. Eur J Cardiothorac Surg 1997;5:881-7.
(12.) Benetti FJ, Mariani MA. Off pump coronary artery bypass surgery. In: Szabo Z, Lewis JE, Fantini GH, Savalgi RS, eds. Cardiovascular surgery. Surgical technology international, Vol. II. San Francisco, CA: Universal Medical Press, 1998:219-26.
(13.) Wu AHB, Apple FS, Gibler WB, Jesse RL, Warshaw MM, Valdes R Jr. National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases. Clin Chem 1999;45:1104-21.
(14.) Press WH, Flannery BP, Teukolsky SA, Vetterling WT. Numerical recipes, 3rd ed. New York: Cambridge University Press, 1987:110-4.
(15.) Van der Laarse A, Vermeer F, Hermens WT, Willems GM, de Neef K, Simoons ML, et al. Effects of early intracoronary streptokinase on infarct size estimated from cumulative enzyme release and on enzyme release rate: a randomized trial of 533 patients with acute myocardial infarction. Am Heart J 1986;112:672-81.
(16.) Banning A, Musumeci F, Penny W, Tovey JA. Reference intervals for cardiac troponin T, creatine kinase and creatine kinase-MB isoenzyme following coronary bypass graft surgery. Ann Clin Biochem 1996;33:561-2.
(17.) Etievent JP, Chocron S, Toubin G, Taberlet C, Alwan K, Clement F, et al. Use of cardiac troponin I as a marker of perioperative myocardial ischemia. Ann Thorac Surg 1995;59:1192-4.
(18.) Harff GA, Van den Bosch MJA, Schonberger JPAM. Influence of mammary artery as a bypass vessel on the results of seven biochemical assays after coronary artery bypass surgery. Ann Clin Biochem 1999;36:180-8.
(19.) Gensini GF, Fusi C, Conti AA, Calamai GC, Montesi GF, Galanti G, et al. Cardiac troponin I and Q-wave perioperative myocardial infarction after coronary artery bypass surgery. Crit Care Med 1998;26:1986-90.
(20.) Alyanakian MA, Dehoux M, Chatel D, Seguret C, Desmonds JM, Durand G, et al. Cardiac troponin I in diagnosis of perioperative myocardial infarction after cardiac surgery. J Cardiothorac Vasc Anesth 1998;12:288-94.
Joost C.J.M. Swaanenburg,  * Bert G. Loef,  Marcel Volmer,  Piet W. Boonstra,  Jan G. Grandjean,  Massimo A. Mariani,  and Anne H. Epema 
 Department of Pathology and Laboratory Medicine,
 Thoracic Center, and
 Department of Anesthesiology, University Hospital Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands;
* address correspondence to this author at: Sint Jans Gasthuis, Clinical Chemical and Hematological Laboratory, Postbus 29, 6000 AA Weert, The Netherlands; e-mail email@example.com
Table 1. Median AUC (range) of the normalized release patterns from the examined biochemical markers after various forms of cardiac surgery. CABG + CPB (a) [greater than or equal to]3 1-2 anas (b) anas (b) Marker (n = 10) (n = 26) Total CK 61(29-153) 97(30-1126) CKMB activity 12 (7-19) (f) 17(10-68) CKMB mass 83 (40-160) (f) 108(72-339) Troponin T 84 (18-166) (f) 124(54-241) Troponin I (AxSYM) 111(78-242) 164(67-234) Troponin I (Access) 116(55-269) 134(19-532) CABG + CPB (a) CABG - CPB (c) All patients 1-2 anas (b) Marker (n = 36) (n = 23) Total CK 90(29-1126) 96(21-267) CKMB activity 16(7-68) (g) 8 (3-14) (h) CKMB mass 104 (40-339) (g) 24 (8-44) (h) Troponin T 106 (18-241) (g) 5 (2-41) (h) Troponin I (AxSYM) 151 (67-242) (g) 6(1-55) (h) Troponin I (Access) 122 (19-532) (g) 14 (1-48) (h) Aorta VR (d) Mitral VR (e) Marker (n = 14) (n = 9) Total CK 100(17-354) 132(26-257) CKMB activity 25(11-138) 45(16-126) CKMB mass 196(97-1280) 268(181-530) Troponin T 198(49-561) 285(193-662) Troponin I (AxSYM) 246(34-1022) 428(322-732) Troponin I (Access) 288(85-1621) 252(146-736) (a) CABG with CPB. (b) Number of anastomoses. (c) CABG without CPB. (d) Aorta valve replacement. (e) Mitral valve replacement. (f) Significantly different from CABG + CPB with three or more anastomoses. (g) Signifcantly different from aorta valve replacement and mitral valve replacement. (h) Significantly different from all other methodologies.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Technical Briefs|
|Author:||Swaanenburg, Joost C.J.M.; Loef, Bert G.; Volmer, Marcel; Boonstra, Piet W.; Grandjean, Jan G.; Mari|
|Date:||Mar 1, 2001|
|Previous Article:||Year-long validation study and reference values for urinary amino acids using a reversed-phase HPLC method.|
|Next Article:||International survey on the use of cardiac markers.|